Zoetis Inc. (NYSE:ZTS) Shares Acquired by Pittenger & Anderson Inc.

Pittenger & Anderson Inc. increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 125,564 shares of the company’s stock after acquiring an additional 2,061 shares during the period. Zoetis makes up about 0.9% of Pittenger & Anderson Inc.’s investment portfolio, making the stock its 26th largest position. Pittenger & Anderson Inc.’s holdings in Zoetis were worth $24,533,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ZTS. Quarry LP grew its stake in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the last quarter. LRI Investments LLC acquired a new position in Zoetis in the 1st quarter valued at $43,000. Fortitude Family Office LLC raised its position in Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after buying an additional 222 shares during the last quarter. Central Valley Advisors LLC acquired a new stake in shares of Zoetis in the 2nd quarter worth $49,000. Finally, EdgeRock Capital LLC purchased a new stake in shares of Zoetis in the second quarter valued at about $56,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Zoetis stock opened at $175.18 on Tuesday. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The firm’s 50-day simple moving average is $188.84 and its 200 day simple moving average is $179.03. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The firm has a market capitalization of $79.37 billion, a PE ratio of 34.28, a P/E/G ratio of 2.82 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the business earned $1.36 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis. On average, equities research analysts predict that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.99%. Zoetis’s dividend payout ratio (DPR) is 33.86%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ZTS. Piper Sandler increased their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus raised their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. increased their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Finally, BTIG Research boosted their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.